Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in: Annals of Surgical Oncology 1/2013

01.01.2013 | Colorectal Cancer

Definition of Patients Presenting a High Risk of Developing Peritoneal Carcinomatosis After Curative Surgery for Colorectal Cancer: A Systematic Review

verfasst von: Charles Honoré, MD, Diane Goéré, MD, Amine Souadka, MD, Frédéric Dumont, MD, Dominique Elias, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

In colorectal cancer, complete cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy achieves encouraging results in early peritoneal carcinomatosis (PC), but this early detection can only be accurately accomplished during a systematic second-look surgery. This costly and invasive approach can only be proposed to selected patients. The objective of this study was to identify risk factors predictive of developing PC after curative surgery for colorectal cancer.

Methods

After a systematic review of the literature published between 1940 and 2011, all clinical studies reporting the incidence of PC after curative surgery for colorectal cancer were searched for factors associated with the primary tumor that were likely to influence the incidence of recurrent PC.

Results

Sixteen clinical studies were considered informative, all nonrandomized, three prospective and 13 retrospective, including 4–395 patients. Overall, the methodological quality of the reported studies was low. Data were available for the following factors: synchronous PC, synchronous ovarian metastases, perforated primary tumor, serosal and/or adjacent organ invasion, histological subtype, and positive peritoneal cytology with reported incidences of recurrent PC between 8 and 75 %. No study was found that mentioned an impact of lymph node invasion, tumor location, laparoscopy, occlusive tumors, or bleeding tumor on recurrent PC.

Conclusions

Evidence regarding the incidence of recurrent PC after curative surgery for colorectal cancer is poor. Emerging data indicate three situations that could result in a real higher risk of recurrent PC: synchronous PC, synchronous isolated ovarian metastases, and a perforated primary tumor.
Literatur
1.
Cass AW, Million RR, Pfaff WW. Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum. Cancer. 1976;37:2861–5.PubMedCrossRef
2.
Minsky BD, Mies C, Recht A, Rich TA, Chaffey JT. Resectable adenocarcinoma of the rectosigmoid and rectum. I. Patterns of failure and survival. Cancer. 1988;61:1408–16.PubMedCrossRef
3.
Mendenhall WM, Million RR, Pfaff WW. Patterns of recurrence in adenocarcinoma of the rectum and rectosigmoid treated with surgery alone: implications in treatment planning with adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 1983;9:977–85.PubMedCrossRef
4.
Gilbert JM, Jeffrey I, Evans M, Kark AE. Sites of recurrent tumour after “curative” colorectal surgery: implications for adjuvant therapy. Br J Surg. 1984;71:203–5.PubMedCrossRef
5.
Willett CG, Tepper JE, Cohen AM, Orlow E, Welch CE. Failure patterns following curative resection of colonic carcinoma. Ann Surg. 1984;200:685–90.PubMedCrossRef
6.
Russell AH, Tong D, Dawson LE, Wisbeck W. Adenocarcinoma of the proximal colon. Sites of initial dissemination and patterns of recurrence following surgery alone. Cancer. 1984;53:360–7.PubMedCrossRef
7.
Jayne DG, Botterill I, Ambrose NS, Brennan TG, Guillou PJ, O’Riordain DS. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:428–32.PubMedCrossRef
8.
Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.PubMedCrossRef
9.
Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–32.PubMedCrossRef
10.
Quenet F, Goéré D, Mehta S, Roca L, Dumont F, Essissen M. Two bi-institutional prospective phase II trials using intraperitoneal oxaliplatin with or without irinotecan during HIPEC following complete cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011;254:294–301.PubMedCrossRef
11.
Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.PubMedCrossRef
12.
Elias D, Glehen O, Pocard M, et al.; Association Française de Chirurgie. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010;251:896–901.PubMedCrossRef
13.
Sugarbaker PH, Schellinx ME, Chang D, Koslowe P, von Meyerfeldt M. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg. 1996;20:585–92.PubMedCrossRef
14.
Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–31.PubMedCrossRef
15.
Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with intraperitoneal chemotherapy for management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.PubMedCrossRef
16.
Elias D, Raynard B, Farkhondeh F, et al. Peritoneal carcinomatosis of colorectal origin. Long term results of intraperitoneal chemohyperthermia with oxaliplatin following complete cytoreductive surgery. Gastroenterol Clin Biol. 2006;30:1200–4.PubMedCrossRef
17.
Elias D, Goéré D, Di Pietrantonio D, et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2008;247:445–50.PubMedCrossRef
18.
Sugarbaker PH. Revised guidelines for second-look surgery in patients with colon and rectal cancer. Clin Transl Oncol. 2010;12:621–8.PubMedCrossRef
19.
American Joint Comitee on Cancer. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.
20.
Sobin LH, Wittekind C, editors. UICC TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002.
21.
22.
Fujiwara A, Noura S, Ohue M, et al. Significance of the resection of ovarian metastasis from colorectal cancers. J Surg Oncol. 2010;102:582–7.PubMedCrossRef
23.
Elias D, Honoré C, Dumont F, et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2011;254:289–93.PubMedCrossRef
24.
Tan KL, Tan WS, Lim JF, Eu KW. Krukenberg tumors of colorectal origin: a dismal outcome—experience of a tertiary center. Int J Colorectal Dis. 2010;25:233–8.PubMedCrossRef
25.
Willett C, Tepper JE, Cohen A, Orlow E, Welch C. Obstructive and perforative colonic carcinoma: patterns of failure. J Clin Oncol. 1985;3:379–84.PubMed
26.
Ogawa M, Watanabe M, Eto K, et al. Clinicopathological features of perforated colorectal cancer. Anticancer Res. 2009;29:1681–4.PubMed
27.
Cheynel N, Cortet M, Lepage C, Ortega-Debalon P, Faivre J, Bouvier AM. Incidence, patterns of failure, and prognosis of perforated colorectal cancers in a well-defined population. Dis Colon Rectum. 2009;52:406–11.PubMedCrossRef
28.
Pande R, Sunga A, Levea C, et al. Significance of signet-ring cells in patients with colorectal cancer. Dis Colon Rectum. 2008;51:50–5.PubMedCrossRef
29.
Hase K, Ueno H, Kuranaga N, Utsunomiya K, Kanabe S, Mochizuki H. Intraperitoneal exfoliated cancer cells in patients with colorectal cancer. Dis Colon Rectum. 1998;41:1134–40.PubMedCrossRef
30.
Yamamoto S, Akasu T, Fujita S, Moriya Y. Long-term prognostic value of conventional peritoneal cytology after curative resection for colorectal carcinoma. Jpn J Clin Oncol. 2003;33:33–7.PubMedCrossRef
31.
Kanellos I, Demetriades H, Zintzaras E, Mandrali A, Mantzoros I, Betsis D. Incidence and prognostic value of positive peritoneal cytology in colorectal cancer. Dis Colon Rectum. 2003;46:535–9.PubMedCrossRef
32.
Noura S, Ohue M, Seki Y, Yano M, Ishikawa O, Kameyama M. Long-term prognostic value of conventional peritoneal lavage cytology in patients undergoing curative colorectal cancer resection. Dis Colon Rectum. 2009;52:1312–20.PubMedCrossRef
33.
Fujii S, Shimada H, Yamagishi S, et al. Evaluation of intraperitoneal lavage cytology before colorectal cancer resection. Int J Colorectal Dis. 2009;24:907–14.PubMedCrossRef
34.
Katoh H, Yamashita K, Sato T, Ozawa H, Nakamura T, Watanabe M. Prognostic significance of peritoneal tumour cells identified at surgery for colorectal cancer. Br J Surg. 2009;96:769–77.PubMedCrossRef
35.
Shepherd NA, Baxter KJ, Love SB. The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology. 1997;112:1096–102.PubMedCrossRef
36.
Luna-Pérez P, Rodríguez-Ramírez SE, de la Barrera MG, Zeferino M, Labastida S. Multivisceral resection for colon cancer. J Surg Oncol. 2002;80:100–4.PubMedCrossRef
37.
Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128:2717–25.PubMedCrossRef
38.
Birnkrant A, Sampson J, Sugarbaker PH. Ovarian metastasis from colorectal cancer. Dis Colon Rectum. 1986;29:767–71.PubMedCrossRef
39.
Hanna NN, Cohen AM. Ovarian neoplasms in patients with colorectal cancer: understanding the role of prophylactic oophorectomy. Clin Colorectal Cancer. 2004;3:215–22.PubMedCrossRef
40.
Buirge RE. Carcinoma of the large intestine. Review of four hundred and sixteen autopsy records. Arch Surg. 1941;42:801–18.CrossRef
41.
Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer. 1950;3:74–85.PubMedCrossRef
42.
Köves I, Vámosi-Nagy I, Besznyák I. Ovarian metastases of colorectal tumours. Eur J Surg Oncol. 1993;19:633–5.PubMed
43.
Chung TS, Chang HJ, Jung KH, et al. Role of surgery in the treatment of ovarian metastases from colorectal cancer. J Surg Oncol. 2009;100:570–4.PubMedCrossRef
44.
Welch JP, Donaldson GA. Perforative carcinoma of colon and rectum. Ann Surg. 1974;180:734–40.PubMedCrossRef
45.
Mandava N, Kumar S, Pizzi WF, Aprile IJ. Perforated colorectal carcinomas. Am J Surg. 1996;172:236–8.PubMedCrossRef
46.
Lee IK, Sung NY, Lee YS, et al. The survival rate and prognostic factors in 26 perforated colorectal cancer patients. Int J Colorectal Dis. 2007;22:467–73.PubMedCrossRef
47.
Schwenter F, Morel P, Gervaz P. Management of obstructive and perforated colorectal cancer. Expert Rev Anticancer Ther. 2010;10:1613–9.PubMedCrossRef
48.
Slanetz CA. The effect of inadvertent intraoperative perforation on survival and recurrence in colorectal cancer. Dis Colon Rectum. 1984;27:792–7.PubMedCrossRef
49.
Kang H, O’Connell JB, Maggard MA, Sack J, Ko CY. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum. 2005;48:1161–8.PubMedCrossRef
50.
Du W, Mah JT, Lee J, Sankila R, Sankaranarayanan R, Chia KS. Incidence and survival of mucinous adenocarcinoma of the colorectum: a population-based study from an Asian country. Dis Colon Rectum. 2004;47:78–85.PubMedCrossRef
51.
Umpleby HC, Ranson DL, Williamson RC. Peculiarities of mucinous colorectal carcinoma. Br J Surg. 1985;72:715–8.PubMedCrossRef
52.
Halvorsen TB, Seim E. Influence of mucinous components on survival in colorectal adenocarcinomas: a multivariate analysis. J Clin Pathol. 1988;41:1068–72.PubMedCrossRef
53.
Yamamoto S, Mochizuki H, Hase K, et al. Assessment of clinicopathologic features of colorectal mucinous adenocarcinoma. Am J Surg. 1993;166:257–61.PubMedCrossRef
54.
Wolfman EF, Astler VB, Coller FA. Mucoid adenocarcinoma of the colon and rectum. Surgery. 1957;42:846–52.PubMed
55.
Okuno M, Ikehara T, Nagayama M, Kato Y, Yui S, Umeyama K. Mucinous colorectal carcinoma: clinical pathology and prognosis. Am Surg. 1988;54:681–5.PubMed
56.
Nissan A, Guillem JG, Paty PB, Wong WD, Cohen AM. Signet-ring cell carcinoma of the colon and rectum: a matched control study. Dis Colon Rectum. 1999;42:1176–80.PubMedCrossRef
57.
Moore GE, Sako K. The spread of carcinoma of the colon and rectum: a study of invasion of blood vessels, lymph nodes and the peritoneum by tumors cells. Dis Colon Rectum. 1959;2:92–7.PubMedCrossRef
58.
Quan SH. Cul-de-sac smears; a follow-up study. Surgery. 1966;60:1170–4.PubMed
59.
Urdaneta LF, Hoyne RF, Loh PM, Fidler R, McGrady D. A search for malignant cells in peritoneal fluid from patients with colorectal adenocarcinoma. Am Surg. 1983;49:76–81.PubMed
60.
Martin JK Jr, Goellner JR. Abdominal fluid cytology in patients with gastrointestinal malignant lesions. Mayo Clin Proc. 1986;61:467–71.PubMedCrossRef
61.
Ambrose NS, MacDonald F, Young J, Thompson H, Keighley MR. Monoclonal antibody and cytological detection of free malignant cells in the peritoneal cavity during resection of colorectal cancer—Can monoclonal antibodies do better? Eur J Surg Oncol. 1989;15:99–102.PubMed
62.
Horattas MC, Evasovich MR, Topham N. Colorectal carcinoma and the relationship of peritoneal cytology. Am J Surg. 1997;174:334–7.PubMedCrossRef
63.
Leather AJ, Kocjan G, Savage F, et al. Detection of free malignant cells in the peritoneal cavity before and after resection of colorectal cancer. Dis Colon Rectum. 1994;37:814–9.PubMedCrossRef
64.
Wind P, Norklinger B, Roger V, Kahlil A, Guin E, Parc R. Long-term prognostic value of positive peritoneal washing in colon cancer. Scand J Gastroenterol. 1999;34:606–10.PubMedCrossRef
65.
Vogel P, Rüschoff J, Kümmel S, et al. Prognostic value of microscopic peritoneal dissemination: comparison between colon and gastric cancer. Dis Colon Rectum. 2000;43:92–100.PubMedCrossRef
66.
Yang SH, Lin JK, Lai CR, et al. Risk factors for peritoneal dissemination of colorectal cancer. J Surg Oncol. 2004;87:167–73.PubMedCrossRef
67.
Lloyd JM, McIver CM, Stephenson SA, Hewett PJ, Rieger N, Hardingham JE. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin Cancer Res. 2006;12:417–23.PubMedCrossRef
68.
Gozalan U, Yasti AC, Yuksek YN, Reis E, Kama NA. Peritoneal cytology in colorectal cancer: incidence and prognostic value. Am J Surg. 2007;193:672–5.PubMedCrossRef
69.
Lee IK, Kim do H, Gorden DL, et al. Prognostic value of CEA and CA 19-9 tumor markers combined with cytology from peritoneal fluid in colorectal cancer. Ann Surg Oncol. 2009;16:861–70.PubMedCrossRef
70.
Nishikawa T, Watanabe T, Sunami E, Tsuno NH, Kitayama J, Nagawa H. Prognostic value of peritoneal cytology and the combination of peritoneal cytology and peritoneal dissemination in colorectal cancer. Dis Colon Rectum. 2009;52:2016–21.PubMedCrossRef
71.
Rekhraj S, Aziz O, Prabhudesai S, et al. Can intra-operative intraperitoneal free cancer cell detection techniques identify patients at higher recurrence risk following curative colorectal cancer resection? A meta-analysis. Ann Surg Oncol. 2008;15:60–8.PubMedCrossRef
72.
Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A. Revised tumor and node categorization for rectal cancer based on Surveillance, Epidemiology, and End Results and rectal pooled analysis outcomes. J Clin Oncol. 2010;28:256–63.PubMedCrossRef
73.
Lujan HJ, Plasencia G, Jacobs M, Viamonte M III, Hartmann RF. Long-term survival after laparoscopic colon resection for cancer: complete five-year follow-up. Dis Colon Rectum. 2002;45:491–501.PubMedCrossRef
74.
Patankar SK, Larach SW, Ferrara A, et al. Prospective comparison of laparoscopic vs. open resections for colorectal adenocarcinoma over a ten-year period. Dis Colon Rectum. 2003;46:601–11.PubMedCrossRef
75.
Kim SH, Park IJ, Joh YG, Hahn KY. Laparoscopic resection of rectal cancer: a comparison of surgical and oncologic outcomes between extraperitoneal and intraperitoneal disease locations. Dis Colon Rectum. 2008;51:844–51.PubMedCrossRef
76.
Wong MT, Ng KH, Lim JF, Ooi BS, Tang CL, Eu KW. 418 Cases of laparoscopic colorectal resections: a single-institution experience and literature review. Singap Med J. 2010;51:650–4.
77.
Oosterling SJ, van der Bij GJ, van Egmond M, van der Sijp JR. Surgical trauma and peritoneal recurrence of colorectal carcinoma. Eur J Surg Oncol. 2005;31:29–37.PubMedCrossRef
78.
Goligher JC, Smiddy FG. The treatment of acute obstruction or perforation with carcinoma of the colon and rectum. Br J Surg. 1957;45:270–4.PubMedCrossRef
79.
Ulin AW, Ehrlich EW. Current views related to management of large bowel obstruction caused by carcinoma of the colon. Am J Surg. 1962;104:463–7.PubMedCrossRef
80.
Chang WY, Burnett WE. Complete colonic obstruction due to adenocarcinoma. Surg Gynecol Obstet. 1962;114:353–6.PubMed
81.
Minster JJ. Comparison of obstructing and nonobstructing carcinoma of the colon. Cancer. 1964;17:242–7.PubMedCrossRef
82.
Loefler I, Hafner CD. Survival rate in obstructing carcinoma of colon. Arch Surg. 1964;89:716–8.PubMedCrossRef
83.
Hickey RC, Hyde HP. Neoplastic obstruction of the large bowel. Surg Clin N Am. 1965;45:1157–63.PubMed
84.
85.
Watters NA. Survival after obstruction of the colon by carcinoma. Can J Surg. 1969;12:124–8.PubMed
86.
Ragland JJ, Londe AM, Spratt JS Jr. Correlation of the prognosis of obstructing colorectal carcinoma with clinical and pathologic variables. Am J Surg. 1971;121:552–6.PubMedCrossRef
87.
Glenn F, McSherry CK. Obstruction and perforation in colo-rectal cancer. Ann Surg. 1971;173:983–92.PubMedCrossRef
88.
Korenaga D, Ueo H, Mochida K, et al. Prognostic factors in Japanese patients with colorectal cancer: the significance of large bowel obstruction—univariate and multivariate analyses. J Surg Oncol. 1991;47:188–92.PubMedCrossRef
89.
McArdle CS, McMillan DC, Hole DJ. The impact of blood loss, obstruction and perforation on survival in patients undergoing curative resection for colon cancer. Br J Surg. 2006;93:483–8.PubMedCrossRef
90.
Dromain C, Leboulleux S, Auperin A, et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging. 2008;33:87–93.PubMedCrossRef
91.
Gunderson LL, Sosin H, Levitt S. Extrapelvic colon—areas of failure in a reoperation series: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1985;11:731–41.PubMedCrossRef
92.
Minton JP, Hoehn JL, Gerber DM, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer. 1985;55:1284–90.PubMedCrossRef
93.
Wangensteen OH. Cancer of the colon and rectum; with special reference to earlier recognition of alimentary tract malignancy; secondary delayed re-entry of the abdomen in patients exhibiting lymph node involvement; subtotal primary excision of the colon; operation in obstruction. Wis Med J. 1949;48:591–7.PubMed
Metadaten
Titel
Definition of Patients Presenting a High Risk of Developing Peritoneal Carcinomatosis After Curative Surgery for Colorectal Cancer: A Systematic Review
verfasst von
Charles Honoré, MD
Diane Goéré, MD
Amine Souadka, MD
Frédéric Dumont, MD
Dominique Elias, MD, PhD
Publikationsdatum
01.01.2013
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2473-5

Weitere Artikel der Ausgabe 1/2013

Annals of Surgical Oncology 1/2013 Zur Ausgabe

Hepatobiliary Tumors

Upregulation of Protein Tyrosine Phosphatase Type IVA Member 3 (PTP4A3/PRL-3) is Associated with Tumor Differentiation and a Poor Prognosis in Human Hepatocellular Carcinoma

Colorectal Cancer

RhoE is Associated with Relapse and Prognosis of Patients with Colorectal Cancer

Melanomas

1 or 2 cm Margins of Excision for T2 Melanomas: Do They Impact Recurrence or Survival?

Hepatobiliary Tumors

Surgical Resection after Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer: A Retrospective Single-center Study

Breast Oncology

Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype

Endocrine Tumors

BRAF V600E Mutation Independently Predicts Central Compartment Lymph Node Metastasis in Patients with Papillary Thyroid Cancer

Neu im Fachgebiet Chirurgie

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

10.04.2024 | Postoperative Schmerztherapie | Nachrichten

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom CME-Kurs
CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur CME-Kurs
CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis CME-Kurs
CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.